Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Scaling/Widening of AUC [Regulatives / Guidelines]

posted by Researcher101 – Egypt, 2021-02-23 21:40 (713 d 08:35 ago) – Posting: # 22224
Views: 2,731

I'm asking if there is any guidance allowing scaling of AUC in case of highly variable drugs and what is the range of scaling if applicable

Edit: See this post #3. [Helmut]

Complete thread:

Scaling/Widening of AUCResearcher101 2021-02-23 20:40 [Regulatives / Guidelines]
- Scaling/Widening of AUC Loky do 2021-02-24 13:13
  - RSABE… Helmut 2021-02-24 14:46
    - RSABE… Loky do 2021-02-24 15:30
      - RSABE… Helmut 2021-02-24 15:47
- Scaling/Widening of AUC Helmut 2021-02-24 15:29
  - Scaling/Widening of AUC Loky do 2021-02-24 16:13
  - Scaling/Widening of AUC dshah 2021-03-16 06:39
    - Scaling/Widening of AUC Helmut 2021-03-16 13:55

Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
21 visitors (0 registered, 21 guests [including 10 identified bots]).
Forum time: 06:15 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce. Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz